Nanoparticles as Potential Novel Therapies for Urinary Tract Infections

Abstract

Urinary tract infection (UTI) is one of the most common reasons for antibiotic treatment. Nevertheless, uropathogens are steadily becoming resistant to currently available therapies. In this context, nanotechnology emerges as an innovative and promising approach among diverse strategies currently under development. In this review we deeply discuss different nanoparticles (NPs) used in UTI treatment, including organic NPs, nanodiamonds, chemical and green synthesized inorganic NPs, and NPs made of composite materials. In addition, we compare the effects of different NPs against uropathogens in vivo and in vitro and discuss their potential impact the in the near future.

Cefotaxime incorporated bimetallic silver-selenium nanoparticles: promising antimicrobial synergism, antibiofilm activity, and bacterial membrane leakage reaction mechanism

“…6. On the other hand, Ag NPs, Se NPs, and Ag-Se NPs exhibited less activity against S. aureus (12, 19, and 17 mm, respectively), E. coli (21,22, and 20 mm, respectively), and P. aeruginosa (18, 9 and 20 mm, respectively) in Fig. 6 which explains the synergistic effect as reported in an earlier study.…”

Surface modification of SiO2 nanoparticles for bacterial decontaminations of blood products

“…More specifically, functionalized SiO2 NPs can be incorporated into the PU matrix used during its synthesis to provide multifunctional capabilities [65]. The coating should have repellent properties so that bacteria cannot attach to the surface of materials coated by MAACs, and it can exhibit antimicrobial activity by binding to proteins associated with bacterial adhesion [66]. In the light of current knowledge on the mechanisms of action of MAACs, SiO2 NPs can bind specifically to saccharides contained in the peptidoglycan layer of bacteria, thus inducing an osmotic change leading to cell death [67].…”

Antibacterial Potential of Bacopa monnieri (L.) Wettst. and Its Bioactive Molecules against Uropathogens—An In Silico Study to Identify Potential Lead Molecule(s) for the Development of New Drugs to Treat Urinary Tract Infections

“…A significant prevalence of UTIs exists across all socioeconomic categories, exacerbating economic pressure for some families. UTIs are one of the most prevalent healthcare-associated infections, with an estimated 150 million people infected worldwide each year, with 13,000 associated deaths [ 8 ]. Although many antibiotics are prescribed for the treatment of UTIs, a major cause for concern is the emergence of drug-resistant strains.…”